<?xml version="1.0" encoding="UTF-8"?>
<p>There are several other pure CBD products in development. CBD gel (ZYN002) is designed by Zynerba
 <sup>®</sup> Pharmaceuticals and is intended to be registered for transdermal use, Fragile X syndrome, adult refractory focal epilepsy, and encephalopathies that are developmental. Bionorica
 <sup>®</sup> has developed a pure CBD crystalline powder from certified seeds of low-THC fiber hemp. Synthetic CBD crystalline powder is also available as an oral capsule formulated by STI Pharmaceuticals along with other forms of products such as CBD oil and inhalation formulation [
 <xref rid="B176-molecules-25-04036" ref-type="bibr">176</xref>,
 <xref rid="B177-molecules-25-04036" ref-type="bibr">177</xref>,
 <xref rid="B178-molecules-25-04036" ref-type="bibr">178</xref>]. Oral solutions of pure CBD in different doses are under clinical trial studies by INSYS Pharmaceuticals, for childhood absence seizures, or as an adjunctive therapy in conjunction with vigabatrin for infantile spasm-type seizures, Prader-Willi syndrome, and anxietylike behavior [
 <xref rid="B179-molecules-25-04036" ref-type="bibr">179</xref>]. Purified CBD is also formulated in seamless gelatin matrix pellets in a dose of 10 and 100 mg CBD (PTL101), by PhytoTech Therapeutics [
 <xref rid="B180-molecules-25-04036" ref-type="bibr">180</xref>].
</p>
